Clinical Trial Update: Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial investigating the effect of Symbicort on histone acetyltransferase and HDAC activity in sputum macrophages for COPD was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: Imperial College London | Conditions: Chronic Obstructive Pulmonary Disease (COPD), Age Matched Healthy Volunteers (Non-smokers) | Phase 4 | Status: WITHDRAWN